Titan Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
TTNP Titan Pharmaceuticals Inc
OCGN Ocugen Inc
ACMR ACM Research Inc
SDY SPDR® S&P Dividend ETF
DIS Walt Disney Co
AAPL Apple Inc
MLM Martin Marietta Materials Inc
GOOG Alphabet Inc
FCNTX Fidelity® Contrafund® Fund
MSFT Microsoft Corp
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Price
Delayed
$2.31
Day's Change
0.07 (3.12%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.40
Day's Low
2.28
Volume
(Light)

Today's volume of 70,498 shares is on pace to be much lighter than TTNP's 10-day average volume of 187,106 shares.

70,498

Company Profile

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
4.69x
Price/Book (MRQ)
4.65x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

April 2021
Current Month
1.2M
Previous Month
1.5M
Percent of Float
13.19%
Days to Cover
4.2747 Days

Share Information

TTNP is in a share class of common stock
Float
9.2M
Shares Outstanding
9.9M
Institutions Holding Shares
20
15.18%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Marc RubinChmn.
  • Katherine Beebe DeVarneyPres.
  • Joseph A. Akers
  • M. David MacFarlane
  • James R. McNab

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.